287 related articles for article (PubMed ID: 29377462)
1. Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib.
Younossi ZM; Stepanova M; Lawitz E; Charlton M; Loomba R; Myers RP; Subramanian M; McHutchison JG; Goodman Z
Liver Int; 2018 Oct; 38(10):1849-1859. PubMed ID: 29377462
[TBL] [Abstract][Full Text] [Related]
2. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
Younossi ZM; Anstee QM; Wai-Sun Wong V; Trauner M; Lawitz EJ; Harrison SA; Camargo M; Kersey K; Subramanian GM; Myers RP; Stepanova M
Gastroenterology; 2021 Apr; 160(5):1608-1619.e13. PubMed ID: 33307033
[TBL] [Abstract][Full Text] [Related]
3. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.
Loomba R; Lawitz E; Mantry PS; Jayakumar S; Caldwell SH; Arnold H; Diehl AM; Djedjos CS; Han L; Myers RP; Subramanian GM; McHutchison JG; Goodman ZD; Afdhal NH; Charlton MR;
Hepatology; 2018 Feb; 67(2):549-559. PubMed ID: 28892558
[TBL] [Abstract][Full Text] [Related]
4. Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis.
Younossi ZM; Stepanova M; Anstee QM; Lawitz EJ; Wai-Sun Wong V; Romero-Gomez M; Kersey K; Li G; Subramanian GM; Myers RP; Djedjos CS; Okanoue T; Trauner M; Goodman Z; Harrison SA
Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2552-2560.e10. PubMed ID: 30779990
[TBL] [Abstract][Full Text] [Related]
5. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
Harrison SA; Wong VW; Okanoue T; Bzowej N; Vuppalanchi R; Younes Z; Kohli A; Sarin S; Caldwell SH; Alkhouri N; Shiffman ML; Camargo M; Li G; Kersey K; Jia C; Zhu Y; Djedjos CS; Subramanian GM; Myers RP; Gunn N; Sheikh A; Anstee QM; Romero-Gomez M; Trauner M; Goodman Z; Lawitz EJ; Younossi Z; ;
J Hepatol; 2020 Jul; 73(1):26-39. PubMed ID: 32147362
[TBL] [Abstract][Full Text] [Related]
6. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
Loomba R; Noureddin M; Kowdley KV; Kohli A; Sheikh A; Neff G; Bhandari BR; Gunn N; Caldwell SH; Goodman Z; Wapinski I; Resnick M; Beck AH; Ding D; Jia C; Chuang JC; Huss RS; Chung C; Subramanian GM; Myers RP; Patel K; Borg BB; Ghalib R; Kabler H; Poulos J; Younes Z; Elkhashab M; Hassanein T; Iyer R; Ruane P; Shiffman ML; Strasser S; Wong VW; Alkhouri N;
Hepatology; 2021 Feb; 73(2):625-643. PubMed ID: 33169409
[TBL] [Abstract][Full Text] [Related]
7. Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
Younossi ZM; Stepanova M; Noureddin M; Kowdley KV; Strasser SI; Kohli A; Ruane P; Shiffman ML; Sheikh A; Gunn N; Caldwell SH; Huss RS; Myers RP; Wai-Sun Wong V; Alkhouri N; Goodman Z; Loomba R
Hepatol Commun; 2021 Jul; 5(7):1201-1211. PubMed ID: 34278169
[TBL] [Abstract][Full Text] [Related]
8. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.
Harrison SA; Abdelmalek MF; Caldwell S; Shiffman ML; Diehl AM; Ghalib R; Lawitz EJ; Rockey DC; Schall RA; Jia C; McColgan BJ; McHutchison JG; Subramanian GM; Myers RP; Younossi Z; Ratziu V; Muir AJ; Afdhal NH; Goodman Z; Bosch J; Sanyal AJ;
Gastroenterology; 2018 Oct; 155(4):1140-1153. PubMed ID: 29990488
[TBL] [Abstract][Full Text] [Related]
9. The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes.
Younossi Z; Aggarwal P; Shrestha I; Fernandes J; Johansen P; Augusto M; Nair S
JHEP Rep; 2022 Sep; 4(9):100525. PubMed ID: 36039144
[TBL] [Abstract][Full Text] [Related]
10. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.
Sanyal AJ; Harrison SA; Ratziu V; Abdelmalek MF; Diehl AM; Caldwell S; Shiffman ML; Aguilar Schall R; Jia C; McColgan B; Djedjos CS; McHutchison JG; Subramanian GM; Myers RP; Younossi Z; Muir AJ; Afdhal NH; Bosch J; Goodman Z
Hepatology; 2019 Dec; 70(6):1913-1927. PubMed ID: 30993748
[TBL] [Abstract][Full Text] [Related]
11. Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis.
Younossi ZM; Stepanova M; Younossi I; Racila A
Clin Gastroenterol Hepatol; 2019 Sep; 17(10):2093-2100.e3. PubMed ID: 30639779
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
Yamamura S; Nakano D; Hashida R; Tsutsumi T; Kawaguchi T; Okada M; Isoda H; Takahashi H; Matsuse H; Eguchi Y; Sumida Y; Nakajima A; Gerber L; Younossi ZM; Torimura T
J Gastroenterol Hepatol; 2021 Mar; 36(3):629-636. PubMed ID: 32627871
[TBL] [Abstract][Full Text] [Related]
13. Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study.
Yilmaz Y; Toraman AE; Alp C; Doğan Z; Keklikkiran C; Stepanova M; Younossi Z
Aliment Pharmacol Ther; 2023 Jan; 57(2):215-223. PubMed ID: 36369643
[TBL] [Abstract][Full Text] [Related]
14. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis.
Sanyal AJ; Anstee QM; Trauner M; Lawitz EJ; Abdelmalek MF; Ding D; Han L; Jia C; Huss RS; Chung C; Wong VW; Okanoue T; Romero-Gomez M; Muir AJ; Afdhal NH; Bosch J; Goodman Z; Harrison SA; Younossi ZM; Myers RP
Hepatology; 2022 May; 75(5):1235-1246. PubMed ID: 34662449
[TBL] [Abstract][Full Text] [Related]
15. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry.
Younossi ZM; Yilmaz Y; Yu ML; Wai-Sun Wong V; Fernandez MC; Isakov VA; Duseja AK; Mendez-Sanchez N; Eguchi Y; Bugianesi E; Burra P; George J; Fan JG; Papatheodoridis GV; Chan WK; Alswat K; Saeed HS; Singal AK; Romero-Gomez M; Gordon SC; Roberts SK; El Kassas M; Kugelmas M; Ong JP; Alqahtani S; Ziayee M; Lam B; Younossi I; Racila A; Henry L; Stepanova M;
Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2296-2306.e6. PubMed ID: 34768009
[TBL] [Abstract][Full Text] [Related]
17. Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt.
Alqahtani SA; Yilmaz Y; El-Kassas M; Alswat K; Sanai F; AlZahrani M; Abaalkhail F; AlShaikh M; Al-Hamoudi WK; Nader F; Stepanova M; Younossi ZM;
J Viral Hepat; 2024 Jun; 31(6):300-308. PubMed ID: 38622910
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
Younossi ZM; Stepanova M; Charlton M; Curry MP; O'Leary JG; Brown RS; Hunt S
Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):122-132. PubMed ID: 28404069
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens.
Younossi ZM; Stepanova M; Nader F; Jacobson IM; Gane E; Nelson D; Lawitz E; Hunt SL
Hepatology; 2014 Jun; 59(6):2161-9. PubMed ID: 24710669
[TBL] [Abstract][Full Text] [Related]
20. The Potential Role of Fatigue in Identifying Patients With NASH and Advanced Fibrosis Who Experience Disease Progression.
Younossi ZM; Stepanova M; Myers RP; Younossi I; Henry L
Clin Gastroenterol Hepatol; 2023 Apr; 21(4):970-977.e1. PubMed ID: 35533993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
